DSMC meets with CytoDyn on roughly Tuesday, Octobe

DSMC meets with CytoDyn on roughly Tuesday, October 13th

PR to announce DSMC recommendation webcast released on Thursday, October 15th

PR to announce DSMC positive recommendation released on Tuesday, October 20th

Trial enrollment on October 19th is 230 patients. (PR came out at 6:00am EDT, so could not capture possible enrollment(s) on October 20th)

The article states “CytoDyn has already registered 235 patients in its trial, and the Data Safety Monitoring Committee (DSMC) has just this week recommended that CytoDyn continue…”

Just this week = the week the public became aware of the DSMCs positive recommendation, which is the week of Monday, October 19th. Let’s assume that the interview occurred that Friday, October 23rd. This is a fair assumption because we know the interview was the same week as the public release of the DSMCs recommendation.

The article goes on to state, “CytoDyn received its positive news from the DSMC early last week…” We know that CytoDyn received the news the week of Monday, October 12th, so this statement reinforces the above timeline.

Based on this sequence of events, it appears to me that the 235 enrolled figure could not have been any later than Friday, October 23rd, unless the interview was on the weekend, which is doubtful as that’s outside business hours, but that would put us at Sunday, October 25th at the absolute latest.

Hopefully we added several more this past week, but even then, it would be nice if we could accelerate things with the U.K. and the new sites in the U.S. The failure, so far, of other drugs in the severe/critical patient cohort could also help.